Diligence memo · auto-generated · as of July 2, 2026
Cresilon, Inc.
Cresilon, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Cresilon, Inc. operates in Biotechnology, based in BROOKLYN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cresilon, Inc. has raised $29M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $29M on 2026-06-26.
Most recent recorded round closed around 2026-06-26.
Valuation (modeled)modeled
Provath models Cresilon, Inc. at approximately $88M (range $58M–$108M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.14× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era. Within the normal band (114% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise under a month ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 74% of Biotechnology peers (4293 compared).
Modeled value ranks above 56% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.